pmid,title,journal,year,drug,disease
40536568,Efficacy and safety of imatinib in patients with COVID-19: a systematic review and meta-analysis.,Wiener klinische Wochenschrift,2025,Imatinib,COVID-19
40452060,National Insights Into Epidemiological Trends and Outcomes of Malignant Neoplasms of the Small Intestine: A Big Data Analysis.,Journal of gastroenterology and hepatology,2025,Imatinib,COVID-19
39985762,Disease-Drug-Drug Interaction of Imatinib in COVID-19 ARDS: A Pooled Population Pharmacokinetic Analysis.,CPT: pharmacometrics & systems pharmacology,2025,Imatinib,COVID-19
39748395,Integrative analyses of mendelian randomization and bioinformatics reveal casual relationship and genetic links between COVID-19 and knee osteoarthritis.,BMC medical genomics,2025,Imatinib,COVID-19
39587918,Evaluating imatinib in severe COVID-19: a systematic review and meta-analysis.,Transactions of the Royal Society of Tropical Medicine and Hygiene,2025,Imatinib,COVID-19
39519351,Vitamin K2 Protects Against SARS-CoV-2 Envelope Protein-Induced Cytotoxicity in Chronic Myeloid Leukemia Cells and Enhances Imatinib Activity.,International journal of molecular sciences,2024,Imatinib,COVID-19
39445010,Increased plasma imatinib exposure and toxicity in chronically treated GIST patients with SARS-CoV-2 infection: a case series.,Frontiers in immunology,2024,Imatinib,COVID-19
39281285,Gastrointestinal tract organoids as novel tools in drug discovery.,Frontiers in pharmacology,2024,Imatinib,COVID-19
39165680,Regorafenib-related erythrocytosis in metastatic extra-gastrointestinal stromal tumor: a case report.,Frontiers in oncology,2024,Imatinib,COVID-19
39024368,"In-silico discovery of common molecular signatures for which SARS-CoV-2 infections and lung diseases stimulate each other, and drug repurposing.",PloS one,2024,Imatinib,COVID-19
38969238,Short- and long-term effects of imatinib in hospitalized COVID-19 patients: A randomized trial.,The Journal of infection,2024,Imatinib,COVID-19
38605258,Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes.,Journal of cancer research and clinical oncology,2024,Imatinib,COVID-19
38503318,"Drugs and natural products for the treatment of COVID-19 during 2020, the first year of the pandemic.",Boletin medico del Hospital Infantil de Mexico,2024,Imatinib,COVID-19
38454628,Pharmacist's role in the management of drug-drug interactions caused by nirmatrelvir/ritonavir in COVID-19 oncohematology patients.,Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,2025,Imatinib,COVID-19
38424569,Imatinib treatment improves hyperglycaemic dysregulation in severe COVID-19: a secondary analysis of blood biomarkers in a randomised controlled trial.,"Critical care (London, England)",2024,Imatinib,COVID-19
38272877,Longitudinal plasma proteomics reveals biomarkers of alveolar-capillary barrier disruption in critically ill COVID-19 patients.,Nature communications,2024,Imatinib,COVID-19
38186640,"Identification of oral therapeutics using an AI platform against the virus responsible for COVID-19, SARS-CoV-2.",Frontiers in pharmacology,2023,Imatinib,COVID-19
38104036,Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors.,Oncology and therapy,2024,Imatinib,COVID-19
38022239,Paradoxical Immune Reconstitution Inflammatory Syndrome in SARS-CoV-2 Infection After Improvement of Chemotherapy-Induced Aplasia.,Cureus,2023,Imatinib,COVID-19
38006751,Predictions based on inflammatory cytokine profiling of Egyptian COVID-19 with 2 potential therapeutic effects of certain marine-derived compounds.,International immunopharmacology,2024,Imatinib,COVID-19
37763683,Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection-A Single Center Survey.,"Medicina (Kaunas, Lithuania)",2023,Imatinib,COVID-19
37659007,"Reply to ""Embracing imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19"".",Angiogenesis,2023,Imatinib,COVID-19
37601670,Management of chronic myelogenous leukemia with COVID-19 and hepatitis B.,Frontiers in oncology,2023,Imatinib,COVID-19
37542399,"Predictors of Mortality among COVID-19 Patients Admitted to Intensive Care Units: A Single-Center Study in Tehran, Iran.",Archives of Iranian medicine,2022,Imatinib,COVID-19
37530975,Embracing Imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19.,Angiogenesis,2023,Imatinib,COVID-19
37337067,SARS-CoV-2 Omicron BA.5.2-infection and COVID-19 in persons with chronic myeloid leukaemia.,Journal of cancer research and clinical oncology,2023,Imatinib,COVID-19
37312588,Drug repurposing for COVID-19: current evidence from randomized controlled adaptive platform trials and living systematic reviews.,British medical bulletin,2023,Imatinib,COVID-19
37296934,Drug Repurposing in Oncology: A Systematic Review of Randomized Controlled Clinical Trials.,Cancers,2023,Imatinib,COVID-19
37291677,"Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial.","Critical care (London, England)",2023,Imatinib,COVID-19
36995225,Amuvatinib Blocks SARS-CoV-2 Infection at the Entry Step of the Viral Life Cycle.,Microbiology spectrum,2023,Imatinib,COVID-19
36986786,Evaluation of In Vitro and In Vivo Antiviral Activities of Vitamin D for SARS-CoV-2 and Variants.,Pharmaceutics,2023,Imatinib,COVID-19
36870577,Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19.,European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,2023,Imatinib,COVID-19
36864189,"A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19.",Cellular & molecular immunology,2023,Imatinib,COVID-19
36819815,COVID-19 in patients with chronic myeloid leukaemia on tyrosine kinase inhibitor therapy: a Honduran observational study.,Ecancermedicalscience,2022,Imatinib,COVID-19
36769193,"Evaluation of In Vitro Distribution and Plasma Protein Binding of Selected Antiviral Drugs (Favipiravir, Molnupiravir and Imatinib) against SARS-CoV-2.",International journal of molecular sciences,2023,Imatinib,COVID-19
36639911,"Baricitinib or imatinib in hospitalized COVID-19 patients: Results from COVINIB, an exploratory randomized clinical trial.",Journal of medical virology,2023,Imatinib,COVID-19
36528708,COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.,Leukemia,2023,Imatinib,COVID-19
36522140,A leap towards personalised therapy of acute lung injury.,The European respiratory journal,2022,Imatinib,COVID-19
36312321,In silico investigation of the therapeutic and prophylactic potential of medicinal substances bearing guanidine moieties against COVID-19.,Chemicke zvesti,2023,Imatinib,COVID-19
36254081,Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: An updated network meta-analysis of 48 randomized controlled trials.,Medicine,2022,Imatinib,COVID-19
36117402,Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy.,Journal of medical virology,2023,Imatinib,COVID-19
36090793,"Putative COVID-19 therapies imatinib, lopinavir, ritonavir, and ivermectin cause hair cell damage: A targeted screen in the zebrafish lateral line.",Frontiers in cellular neuroscience,2022,Imatinib,COVID-19
35998027,Imatinib as a Tool Against COVID-19: A Balancing Act Between Effectiveness and Cardiac Safety.,Journal of cardiovascular pharmacology,2022,Imatinib,COVID-19
35989789,Co-occurrence of CML Blast Crisis and Severe COVID 19 Infection: A Case Report.,Cureus,2022,Imatinib,COVID-19
35976136,"Cardiac Safety of Imatinib for the Treatment of COVID-19: A Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial.",Journal of cardiovascular pharmacology,2022,Imatinib,COVID-19
35896211,Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients.,The European respiratory journal,2022,Imatinib,COVID-19
35818053,A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase.,Journal of hematology & oncology,2022,Imatinib,COVID-19
35756668,Delayed Diagnosis and Multi-TKI Intolerance: A Case Report of CML Concurrent With COVID-19.,Frontiers in oncology,2022,Imatinib,COVID-19
35634954,"Artesunate, imatinib, and infliximab in COVID-19: A rapid review and meta-analysis of current evidence.","Immunity, inflammation and disease",2022,Imatinib,COVID-19
35460539,Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS-CoV-2 Infection: A Case Study With Imatinib.,Journal of clinical pharmacology,2022,Imatinib,COVID-19
